On April 22, 2026, the Japanese Industrial Standard JIS T 0101:2026 officially came into effect, adding a mandatory test item for ‘accelerated aging of zero-point drift’, requiring medical pressure sensors to have a zero-point drift of ≤0.1%FS under extreme temperature and humidity conditions of 72 hours, 60℃, and 95%RH. This requirement directly affects medical sensor export enterprises targeting the Japanese market, and in particular constitutes a substantive compliance barrier for medical device manufacturers, OEM factories, and trade service providers serving Japan.

Event Overview

The Japanese Industrial Standard JIS T 0101:2026 officially came into effect on April 22, 2026. The new regulation explicitly lists the ‘accelerated aging of zero-point drift’ test as a mandatory item, with test conditions of 72 hours, 60℃, 95% relative humidity（RH）, and an acceptance limit of zero-point drift not exceeding 0.1% of full scale（FS）. Products that fail this test cannot obtain marketing approval from the Pharmaceuticals and Medical Devices Agency（PMDA）in Japan. Publicly available information currently shows that only about 17% of Chinese export enterprises have the qualifications for this test; some Japanese distributors have already suspended acceptance of Chinese-made medical pressure sensor shipments that are not accompanied by pre-test reports.

Which Segments Are Affected

Direct Trading Enterprises

Because the export destination is Japan and the product falls within the scope of JIS T 0101（medical pressure sensors）, its customs declaration, customs clearance, and market access processes are directly constrained by the new regulation. The impact is mainly reflected in: export orders may be rejected or delayed in release; additional third-party test reports compliant with JIS T 0101:2026 are required; aging test data must be supplemented in PMDA registration documents, otherwise device classification and marketing approval applications cannot be completed.

Processing and Manufacturing Enterprises

Enterprises engaged in the design, assembly, or calibration of medical pressure sensors must ensure that their products meet the new regulatory requirements for performance stability before leaving the factory. The impact is mainly reflected in: existing zero-point temperature drift compensation processes may fail to meet the stringent conditions of 72h@60℃/95%RH; key materials such as sensor packaging materials, adhesives, and PCB protective coatings need to be re-validated for resistance to damp-heat aging; production lines need to add zero-point calibration steps before/after aging, affecting delivery cycles and yield control.

Channel Distribution Enterprises

Including Japanese medical device importers, distributors, and brand operators. The impact is mainly reflected in: if upstream supply lacks pre-test reports, there will be a risk of shipments being held at the port upon receipt; contract performance clauses need to be updated simultaneously to clarify test responsibility allocation and report delivery milestones; some small and medium-sized distributors, due to a lack of technical review capability, are shifting to accepting only products supplied directly by factories that have already obtained JIS certification.

Supply Chain Service Enterprises

Covering testing laboratories, certification consulting institutions, and compliance training service providers. The impact is mainly reflected in: the number of domestic third-party laboratories capable of conducting JIS T 0101:2026 zero-point drift aging tests is limited, placing pressure on service capacity; demand for related technical interpretation and test method training is rising in the short term; some institutions have already launched cross-compliance pathway mapping services for standards such as JIS and ISO 13485, IEC 60601-2-57.

What Key Points Should Relevant Enterprises or Practitioners Focus On, and How Should They Respond at Present

Confirm Whether Your Product Falls Within the Scope of JIS T 0101:2026

Not all pressure sensors are regulated——only models used for ‘medical device’ purposes as defined under the Pharmaceutical and Medical Device Act（such as blood pressure monitoring modules, ventilator airway pressure sensors, and fluid circuit pressure feedback for dialysis equipment）and submitted by Japanese importers for PMDA approval are applicable. Enterprises should verify the product’s intended use statement, Japanese-language instructions, and PMDA classification catalog to avoid misjudging compliance obligations.

Prioritize Pre-testing and Retain Complete Raw Data

Given that only about 17% of Chinese export enterprises have the required qualifications, it is recommended that enterprises that have not yet obtained certification immediately commission laboratories recognized by Japan（such as those recognized by JAB）or laboratories with JIS comparison capabilities to conduct pre-testing; during the testing process, the full temperature and humidity curves, zero-point reading sequences, and environmental chamber calibration certificates must be recorded throughout, and these raw data will form a key part of the evidence chain for subsequent PMDA review.

Evaluate the Adaptability of Key Materials and Processes to Damp-Heat Aging Resistance

Excessive zero-point drift often results from packaging stress release, medium absorption and expansion, or micro-creep deformation of solder joints. Enterprises should focus on rechecking: protective gel for silicon piezoresistive chips, conformal coating in wire bonding areas, housing sealing ring materials（such as EPDM vs. FKM）, PCB substrate TG value, and surface treatment processes. When necessary, initiate small-batch process validation rather than relying solely on supplier-claimed parameters.

Work with Japanese Importers to Update Technical Documents and Responsibility Agreements

Some distributors have already suspended receiving goods, indicating that downstream parties have substantively implemented the new regulation. Exporters need to clarify with Japanese parties: which party provides the test report, how costs are to be borne, and the disposal mechanism for nonconforming batches, and add aging test sections to Japanese-language technical documents（such as IFU, Design Dossier summaries）to ensure consistency in technical communication.

Editorial Viewpoint / Industry Observation

From an analytical perspective, this revision of JIS T 0101:2026 is not an isolated technical upgrade, but rather an explicit manifestation of Japan’s regulatory logic for the long-term reliability of active medical sensors——shifting the focus from static accuracy to long-term stability under extreme environments. From an observational perspective, although this standard is a voluntary industrial standard, because PMDA treats it as a substantive technical basis for marketing approval, it has in practice already acquired quasi-mandatory effect. From an industry perspective, this is more like a compliance outcome that has already taken effect, rather than a policy signal still awaiting observation: distributor suspensions, tight testing resources, and the low proportion of qualified enterprises have all already occurred. What deserves more attention at present is whether similar aging test requirements will be extended in subsequent revisions of JIS T 0102（medical flow sensors）or JIS T 0103（medical temperature sensors）, and whether PMDA will incorporate this test into QMS flight inspection sampling items.

Conclusion
The implementation of JIS T 0101:2026 marks Japan’s market access management for medical pressure sensors entering a new stage centered on ‘environmental robustness’. It is not a routine standard update, but a compliance pressure test aimed at the real capabilities of the export supply chain. At present, it is more appropriate to understand it as follows: medical sensors exported to Japan have moved from the stage of ‘being able to measure accurately’ to the stage of ‘remaining stable’, and enterprises need to move aging reliability verification forward into the R&D and mass production stages, rather than treating it merely as a remedial customs clearance measure.

Information Source Notes
Main sources: the JIS T 0101:2026 standard text issued by the Japanese Industrial Standards Committee（JISC）; technical review guidelines on medical device marketing approval published on the official website of the Pharmaceuticals and Medical Devices Agency（PMDA）（public version as of April 2026）; and distributor operational developments verified by industry information sources（anonymous channels）. Matters to continue observing: whether the JIS standard will subsequently be upgraded into mandatory regulation; whether other Asian markets（such as South Korea MFDS and Singapore HSA）will follow up with similar testing requirements.